GLP1R and obesity due to melanocortin 4 receptor deficiency: The protective effect of GLP-1 RAs was particularly evident in patients with obesity (aHR: 0.61, 95% CI: 0.50–0.77), whereas no significant benefit was noted in non-obese individuals (aHR: 0.94, 95% CI: 0.67–1.31).